Ravindra Mehta, MD
Psychiatry · Brownsville, PANPI 1063599835
Payments from drug & device makers
Across 829 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$7K
- Vanda Pharmaceuticals Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Lundbeck LLC$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- plus $4K from 18 others
What the payments were for
- Speaking & faculty fees$3,28318%
- Travel & lodging$8445%
- Food & beverage$14,01776%
- Education$3332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 168 | $6,866 |
| Vanda Pharmaceuticals Inc. | 92 | $1,821 |
| Teva Pharmaceuticals USA, Inc. | 71 | $1,600 |
| Lundbeck LLC | 104 | $1,488 |
| Johnson & Johnson | 74 | $1,207 |
| Alkermes, Inc. | 50 | $1,086 |
| Neurocrine Biosciences, Inc. | 54 | $996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $556 |
| Axsome Therapeutics, Inc. | 19 | $524 |
| Supernus Pharmaceuticals, Inc. | 63 | $457 |
| E.r. Squibb & Sons, L.L.C. | 16 | $353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $302 |
| Avanir Pharmaceuticals, Inc. | 19 | $271 |
| Corium, LLC | 12 | $195 |
| Sunovion Pharmaceuticals Inc. | 19 | $171 |
| Idorsia Pharmaceuticals US Inc | 6 | $131 |
| Aurinia Pharma U.S., Inc. | 1 | $106 |
| AbbVie(2 entities) | 4 | $82 |
| Almatica Pharma LLC | 4 | $77 |
| Indivior Inc. | 4 | $67 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $54 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Eisai Inc. | 1 | $19 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,477 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 117 | $360,731 |
| AustedoDeutetrabenazine | 38 | $256,417 |
| IngrezzaValbenazine Tosylate | 22 | $178,237 |
| Abilify MaintenaAripiprazole | 24 | $69,871 |
| NuplazidPimavanserin Tartrate | 12 | $61,884 |
| CaplytaLumateperone Tosylate | 38 | $61,613 |
| VraylarCariprazine Hcl | 29 | $39,313 |
| Clozapine | 440 | $35,409 |
| RexultiBrexpiprazole | 24 | $35,315 |
| TrintellixVortioxetine Hydrobromide | 92 | $32,457 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,538 |
| Divalproex Sodium | 620 | $25,497 |
| Olanzapine OdtOlanzapine | 64 | $18,565 |
| AmantadineAmantadine Hcl | 225 | $16,907 |
| Chlorpromazine Hcl | 21 | $13,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,207 | $360,731117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,600 | $256,41738 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $996 | $178,23722 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $6,866 | $105,18648 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $556 | $61,61338 claims |
| AbbVieVraylar, Namzaric | $82 | $46,25841 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $302 | $32,45792 claims |
| Alkermes, Inc.Lybalvi | $1,086 | $28,53818 claims |
| Axsome Therapeutics, Inc.Auvelity | $524 | $8,50312 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $131 | $5,53213 claims |
| Almatica Pharma LLCSertraline Hcl | $77 | $2,913276 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Brownsville
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.